Fibrosis, Liver, Obesity, Steatosis
Conditions
Brief summary
Background: The XL probe of FibroScan was recently developed to realize liver stiffness measurements (LSM) in overweight patients. Severe obese patients have a high prevalence of liver injuries and could benefit of liver evaluation prior to bariatric surgery. Objectives: Assess the FibroScan applicability, reliability and diagnostic performances in severe obese patients' candidates for bariatric surgery.
Interventions
DEVICEEvaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery
Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery
Sponsors
Echosens
European Georges Pompidou Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Severe obese patients candidate to bariatric surgery with no history of liver disease have a large prevalence of liver lesions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Elasticity measured with the Fibroscan XL | 3 years | Liver elasticity will be measured non-invasively with Fibroscan. As this is a non-invasive measure, no adverse effects are expected. No treatment planned. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 53/5000 Evolution of elasticity after bariatric surgery | 3 years | The evolution of elasticity will be measured non-invasively with fibroscan after bariatric surgery. NO adverse effects are expected in relation to this measure. |
Outcome results
None listed